NEW YORK, Nov. 18 Reportlinker.com announces that a new market research report is available in its catalogue.
Drug-Eluting Stents - Global Market Opportunities
Advertisement
http://www.reportlinker.com/p0164240/Drug-Eluting-Stents---Global-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
Advertisement
Increasing acceptance of stents as viable treatment option, expanding patient population seeking drug-eluting stents, and higher reimbursement coverage are key factors driving growth of drug-eluting stents. Development of innovative treatment methods and preventive measures for coronary diseases, obesity, and diabetes are few factors influencing the long-term growth prospects of the drug-eluting stents market.
Through registering significant growth in the recent past, incidents of adverse effects such as in-stent thrombosis is expected to significantly restrict future market growth. In-stent thrombosis is a common long-term adverse effect of DES where patients develop clots. Although in-stent thrombosis cases occur rarely, they are highly fatal. On the contrary, bare-metal stents do not pose such threats thereby augmenting its usage in interventional management. The rise in in-stent thrombosis cases paves the way for anti-thrombotic therapies. Moreover, drug-eluting stents faces stiff competition from advanced and safer technologies such as tiny wire mesh tubes.
These and other market data and trends are presented in "Drug-Eluting Stents: Global Market Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
DRUG-ELUTING STENTS BMR-1040
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. MARKET OVERVIEW 4
Current and Future Analysis 4
Major Issues and Trends 5
Drug-Eluting Stents Transforming the Scenario of
Interventional- Cardiology Market 5
Adverse Effects Restrict Market Growth 5
Innovation and Development Drive Market Growth 6
High Price of DES - A Major Impediment to Rapid Development 6
Potential Decline in Hospital Revenues 6
Glaring Lack of Health-Related Initiatives World Over 7
Bioabsorbable Stents Closer to Reality Than Expected 7
3. PRODUCT FACTS 8
Major Drug-Eluting Stent Products in the Market 8
4. COMPETITIVE SCENARIO 9
Drug-Eluting Stents-Competitive Arena 9
Market Dominated by Small Band of Players 10
Cordis (A Johnson & Johnson Company) 10
Cypher Leads the Drug-Eluting Stent Market 10
Boston Scientific 10
Taxus Beats Cypher in the US 10
5. REGULATORY ENVIRONMENT 11
FDA Framework 11
FDA to Monitor Drug-Eluting Stents 11
Issues Raised by FDA Regarding the Safety of Stent 11
6. CORPORATE DEVELOPMENTS 11
MIV Therapeutics Acquires Biosync Scientific 11
J & J Acquires Conor Medsystems 12
Lombard Collaborates With S&N 12
India Establishes Asia's first Catheter and Stent Unit 12
Abbott Requests FDA Approval for Xience 12
Brookwood and TTV Start Joint Venture 12
SurModics Acquires Brookwood Pharmaceuticals, Inc 13
ARIAD Collaborates with ICON Medical 13
Biosensors Acquires 50% Stake in JWMS 13
Boston Completes European and Intercontinental Enrollment Phases 14
FDA Approves Boston Scientifis's Taxus Stent with Extended
Shelf Life 14
Abbott Launches Drug-Eluting Coronary Stent 14
Boston Introduces Taxus(R) Express2(TM) in Japan 14
7. MAJOR PLAYERS 15
Abbott Vascular (USA) 15
Angiotech Pharmaceuticals, Inc (Canada) 15
AngioDynamics® Inc. (USA) 15
Boston Scientific, Inc. (USA) 15
Boston Scientific Cardiac Rhythm Management (USA) 16
Biocompatibles International Plc (UK) 16
Biosensors International Pte Ltd. (Singapore) 16
Cordis Corporation (USA) 16
Implant Sciences Corporation (USA) 17
Medtronic, Inc. (USA) 17
MIV Therapeutics Inc (Canada) 17
SurModics, Inc. (USA) 17
8. GLOBAL MARKET ANALYTICS 18
9. THE UNITED STATES 19
Issues and Trends 19
US Healthcare Ideology 19
The Important Role of Medicaid in the US 19
Drug-Eluting Stents-Competitive Arena 20
Leading DES Products in the Market 20
Cypher - First to Market 20
Taxus Beats Cypher 20
Regulatory Environment 20
FDA Framework 20
Issues Raised by FDA Regarding the Safety of Stent 21
10. JAPAN 21
Healthcare System in Japan 21
11. EUROPE 23
a. France 25
b. Germany 25
c. Italy 26
d. The United Kingdom 27
e. Spain 27
f. Rest of Europe 28
12. REST OF WORLD 29
EXHIBITS
Table 1: Percentage Breakdown of Leading Drug Eluting Stents
Brands in the World-2006
Table 2: Percentage Breakdown of Leading Players in the Global
Drug Eluting Stents Market -2008
Table 3: Global Drug-Eluting Stents Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown of Global Drug-Eluting Stents
Market by Region for the Years 2008 & 2012
Table 5: Percentage Breakdown of Major Players in the US
Market for Drug Eluting Stents - 2008
Table 6: Drug-Eluting Stents Market in the US: 2007-2015
(Sales in US$ Million)
Table 7: Percentage Breakdown of Major Players in the Japanese
Market for Drug Eluting Stents -2008
Table 8: Drug-Eluting Stents Market in Japan: 2007-2015 (Sales
in US$ Million)
Table 9: Percentage Breakdown of Major Players in the European
Market for Drug Eluting Stents -2008
Table 10: Drug-Eluting Stents Market by Region in Europe:
2007-2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Drug-Eluting Stents Market
by Region in Europe for the Years 2008 & 2012
Table 12: Drug-Eluting Stents Market in France: 2007-2015
(Sales in US$ Million)
Table 13: Drug-Eluting Stents Market in Germany: 2007-2015
(Sales in US$ Million)
Table 14: Drug-Eluting Stents Market in Italy: 2007-2015
(Sales in US$ Million)
Table 15: Drug-Eluting Stents Market in the UK: 2007-2015
(Sales in US$ Million)
Table 16: Drug-Eluting Stents Market in Spain: 2007-2015
(Sales in US$ Million)
Table 17: Drug-Eluting Stents Market in Rest of Europe:
2007-2015 (Sales in US$ Million)
Table 18: Drug-Eluting Stents Market in Rest of World:
2007-2015 (Sales in US$ Million)
COMPANIES PROFILED
To order this report:
Drug-Eluting Stents - Global Market Opportunities
http://www.reportlinker.com/p0164240/Drug-Eluting-Stents---Global-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
More market research reports here!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
